Cabometyx 40 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FMEJ1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $35,258
Award facts
- Contract value 100% obligated
- $35,257.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for CABOMETYX 40 mg tablets (30-count units) valued at $35,257.72 under a firm fixed-price contract structure. The award, issued on February 4, 2026, with an ultimate completion date of February 5, 2026, was made without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support Department of Defense medical supply needs worldwide.
DMS Pharmaceutical Group serves as one of multiple regional prime vendor contractors under the PPV-G GEN V program, which was established to enable efficient procurement of comprehensive pharmaceutical products—including branded and generic prescription medications, biologics, and medical consumables—across military healthcare facilities globally. The company's substantial federal contracting activity and demonstrated performance on numerous delivery orders across diverse therapeutic categories position it as a critical supplier within the federal pharmaceutical supply chain. The underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period followed by three 30-month option periods.
Quick answers
Who was awarded contract SPE2DR26FMEJ1?
SPE2DR26FMEJ1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FMEJ1 worth?
The government has obligated $35,258 on SPE2DR26FMEJ1.
Is contract SPE2DR26FMEJ1 an order under another contract?
Yes. SPE2DR26FMEJ1 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEJ1 competed?
The extent of competition for SPE2DR26FMEJ1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award